Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 in the Acute Treatment of Migraine

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Event Study to Evaluate the Safety, Tolerability, and Efficacy of PUR3100 in the Acute Treatment of Migraine

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Pulmatrix

Most Recent Events

  • 15 May 2024 According to a Pulmatrix media release, the company is currently looking at opportunities to finance or partner PUR 3100 to initiate a potential Phase 2 clinical study.
  • 28 Mar 2024 According to a Pulmatrix media release, the planned Phase 2 trial builds on the Phase 1 trial results.
  • 19 Sep 2023 According to a Pulmatrix media release, U.S. Food and Drug Administration (FDA) has accepted PUR3100 investigational new drug (IND) application and the Company has received a study may proceed letter for this phase 2 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top